Sanofi
- Country
- ๐ซ๐ทFrance
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 420
- Registration Number
- NCT06181435
- Locations
- ๐บ๐ธ
Center for Dermatology and Plastic Surgery- Site Number : 8401119, Scottsdale, Arizona, United States
๐บ๐ธTorrance Clinical Research- Site Number : 8401027, Lomita, California, United States
๐บ๐ธSavin Medical Group, LLC- Site Number : 8401085, Miami, Florida, United States
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 500
- Registration Number
- NCT06169527
- Locations
- ๐ซ๐ท
Investigational Site Number: 2500048, Levallois-Perret, France
๐ซ๐ทInvestigational Site Number: 2500041, Amiens, France
๐ซ๐ทInvestigational Site Number: 2500037, Angers, France
Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 53
- Registration Number
- NCT06159452
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT06145373
- Locations
- ๐จ๐ณ
Investigational Site Number : 1580001, Taipei, Taiwan
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 260
- Registration Number
- NCT06143891
- Locations
- ๐บ๐ธ
Northwestern University- Site Number : 8400017, Chicago, Illinois, United States
๐บ๐ธUniversity of Kentucky Chandler Medical Center- Site Number : 8400024, Lexington, Kentucky, United States
๐บ๐ธKarmanos Cancer Institute - Detroit- Site Number : 8400013, Detroit, Michigan, United States
A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT06143904
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1400
- Registration Number
- NCT06141473
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham- Site Number : 8401135, Birmingham, Alabama, United States
๐บ๐ธNorth Central Neurology Associates- Site Number : 8401100, Cullman, Alabama, United States
๐บ๐ธSt. Joseph's Hospital and Medical Center- Site Number : 8401139, Phoenix, Arizona, United States
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 858
- Registration Number
- NCT06141486
- Locations
- ๐บ๐ธ
Phoenix Neurological Associates - Phoenix- Site Number : 8400074, Phoenix, Arizona, United States
๐บ๐ธImaging Endpoints- Site Number : 8400050, Scottsdale, Arizona, United States
๐บ๐ธSutter East Bay Medical Foundation - Berkeley- Site Number : 8400134, Berkeley, California, United States
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 420
- Registration Number
- NCT06130566
- Locations
- ๐ง๐ท
CCBR / IBPClin - Instituto Brasil de Pesquisa Clรญnica- Site Number : 0760018, Rio de Janeiro, Brazil
๐จ๐ฆInvestigational Site Number : 1240040, Surrey, British Columbia, Canada
๐จ๐ฆInvestigational Site Number : 1240033, Ajax, Ontario, Canada
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT06118099
- Locations
- ๐บ๐ธ
Medical Dermatology Specialists Site Number : 8400002, Phoenix, Arizona, United States
๐บ๐ธCenter for Dermatology Clinical Research Site Number : 8400010, Fremont, California, United States
๐บ๐ธCorazon USA, LLC (DBA Life Clinical Trials) Site Number : 8400011, Margate, Florida, United States